Priority Review Voucher (PRV): how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What PRV is
Origin and authorising body. United States Food and Drug Administration, Priority Review Voucher programmes for tropical diseases (FDAAA 2007), rare paediatric diseases (FDASIA 2012), and medical countermeasures (21st Century Cures Act 2016). The authorising body for each individual case is the United States Food and Drug Administration (FDA), acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. The FDA awards Priority Review Vouchers (PRVs) to sponsors of medicines approved for tropical diseases (under the FDAAA 2007), rare paediatric diseases (under FDASIA 2012), and medical countermeasures (under the 21st Century Cures Act 2016). A PRV entitles the holder to a priority review (6-month review timeline rather than the standard 10-month) for any subsequent NDA or BLA. PRVs are transferable; sponsors commonly sell PRVs in secondary markets at prices that have historically ranged from approximately USD 67 million to over USD 300 million per voucher.
Priority Review Voucher is a regulatory incentive programme, not a patient-access pathway. It encourages manufacturers to invest in development of medicines for neglected tropical diseases, rare paediatric diseases, and medical countermeasures by providing a financial reward (the transferable voucher) at the point of approval. The patient-access implication is indirect: PRV-bearing approvals tend to generate more development activity in the relevant therapeutic areas, which over time translates into more medicines becoming available through standard regulatory channels.
PRVs do not change the supply or access route for any individual patient. Once a medicine is approved by the FDA, patients access it through standard US prescription channels or, for cross-border patients, through named-patient and personal-import frameworks. The PRV reward sits with the manufacturer and influences future development decisions rather than current patient access. This page is included in our pathway catalogue for completeness; the cross-border operational implications are limited to the indirect incentive effect.
This page consolidates Reserve Meds's operational view of the Priority Review Voucher framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Priority Review Voucher-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use PRV
PRV programmes are used by manufacturers as part of their development planning. Patient-facing involvement is none; the framework operates entirely between the FDA and the manufacturer.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under PRV
Tropical diseases (malaria, tuberculosis, neglected tropical diseases per WHO list), rare paediatric diseases (life-threatening or seriously debilitating diseases affecting children, with the relevant criteria), and medical countermeasures.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Priority Review Voucher import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Priority Review Voucher framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Priority Review Voucher dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Priority Review Voucher clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Priority Review Voucher dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Not applicable (not a patient-access pathway) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Not applicable (not a patient-access pathway) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Not applicable (not a patient-access pathway) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Not applicable (not a patient-access pathway) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Not applicable (not a patient-access pathway) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Not applicable (not a patient-access pathway) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Not applicable (not a patient-access pathway) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Not applicable (not a patient-access pathway) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Not applicable (not a patient-access pathway) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Not applicable (not a patient-access pathway) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Priority Review Voucher authorisation as the legal basis for import but does recognise a Priority Review Voucher authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A PRV application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- Standard FDA NDA or BLA documentation.
- PRV designation request as part of the application.
- Post-approval reporting per the relevant PRV statute.
Typical timeline
PRV designation runs on the standard FDA approval timeline (typically 10 months for standard review, 6 months for priority review). The PRV is issued at the point of approval.
Costs and reimbursement
PRV programme does not directly affect patient costs. Indirectly, the financial incentive supports development of medicines in neglected therapeutic areas, which can over time make more medicines available.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Priority Review Voucher cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Priority Review Voucher framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.